Page 11 - Flipbook

Targeted therapies have improved OS in mRCC

Before VEGF-Targeted Therapies (IFN-ɑ) VEGF-Targeted Therapies Median

Median Risk Group No. Factors Survival
1.0 Survival 100 Favourable 0 43 months
Intermediate 1-2
Proportion surviving
0 risk factor (n = 80) 30 months Poor 3-6 23 months
0.8 1 or 2 risk factors (n = 269) 14 months 8 months
3, 4 or 5 risk factors (n = 88) 5 months 80 P < 0.0001
OS, % 60
0.6

0.4 40

0.2 20

0.0 0
0 2 4 6 8 10 14 16 0 12 24 36 48 60

Time from start of IFN-α, years Time since start of treatment, months
*Risk factors KPS <80%, time from diagnosis to IFN-α <1 year, low *Risk factors for survival included anaemia, thrombocytosis, neutrophilia,
serum haemoglobin, high corrected calcium (>2.5 mmol/liter [10 hypercalcaemia, KPS <80%, and <1 year from diagnosis to treatment.
mg/dl]), high LDH (>1.5× ULN).
Motzer RJ et al. J Clin Oncol. 2002;20:289-296. Heng DY et al. Lancet Oncol. 2013;14:141-148.